Heron Therapeutics, Inc. (NASDAQ: HRTX) announced a second-quarter 2026 net revenue of $37.7 million, reflecting a 9% growth from previous quarter numbers. Although revenue growth is noteworthy, it falls short of the anticipated consensus estimate of EPS at $0.01, as the reported EPS stands …
The company aims to avoid the costs and uncertainties of prolonged legal battles, particularly following scrutiny over the GRAIL acquisition process. This move may help bolster investor confidence, especially as the company's stock has demonstrated substantial year-to-date growth of 39.9%.
Certara, Inc. (Nasdaq: CERT) announced a significant correction to its previousEarningsrelease, adjusting the reported EBITDA for its divested Regulatory and Medical Writing business from $17 million to $23 million, accounting for unallocated overhead costs. Investors must note this revision as it reflects more accurately …
Clene Inc. (Nasdaq: CLNN) reportedEarnings Per Shareof a negative value for the quarter ending in the first quarter, outperforming the consensus estimate of a more negative figure. The share price moved lower during the session, reflecting market sensitivity to upcoming regulatory outcomes.
This financial strain occurred even as the company invested aggressively in its pipeline, particularly in securing regulatory approvals. The reportedEarnings Per Shareof $-0.60 fell short compared to the consensus estimate of $-0.55, marking a disappointing quarter. Despite these financial losses, Cogent’s stock has seen …
Coya Therapeutics, Inc. (Nasdaq: COYA) appointed Mark H. Pavao to its audit committee on Aug. 6, 2026, marking the 11th director change recorded since August 2022. The appointment expands the committee to four members, joining Dr. Dov Goldstein as chair, Dr. Ann Lee and …
CVS Health Corporation (NYSE: CVS) reported total revenues for the second quarter of 2026, increasing to $106.1 billion, representing a 7.3% year-over-year rise.Diluted Earnings per Share(EPS) for the quarter stood at $2.31, up significantly from $0.80 in the same period last year. The growth …
Cytosorbents Corp. (Nasdaq: CTSO) experienced insider buying totaling $148,898, reflecting renewed confidence from itsLeadershipas the company combats a tumultuous market. These transactions, recorded across three trades in the last 60 days, come as the stock grapples with a difficult performance, having plummeted 45.1% year-to-date. …
Cardinal Health Inc. has appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. She will replace Mary Scherer, who will remain in the role until then. Zielinski's previous experience includes key positions at Baxter International and Sysco Corporation, bolstering her credibility as …
- Company eliminated over $125 million of debt in the past six months, bolstering its balance‑sheet strength. - GAGA’s loss from continuing operations increased to $89.1 million, compared with $83.8 million a year earlier. - President and CEO Edward A. Pesicka will retire by …